Vaginal Progesterone to Prevent Preterm Delivery in Women With Preterm Labor (4P)

This study has been terminated.
Sponsor:
Collaborators:
Centre Hospitalier Universitaire Vaudois
University Hospital Inselspital, Berne
Basel Women’s University Hospital
University of Zurich
Kantonsspital Chur
Cantonal Hospital of St. Gallen
Luzerner Kantonsspital
Kantonsspital Winterthur KSW
Besins Laboratory, Belgium
Hospital Bernardino Rivadavia Buenos Aires
Hospital Carlos G. Durand Buenos Aires
CEMIC Buenos Aires
Hospital Donación Francisco Santojanni Buenos Aires
Hospital Dr. Cosme Argerich Buenos Aires
Hospital Dr. T. Alvarez Buenos Aires
Hospital Italiano de Buenos Aires
Hospital J. M. Penna Buenos Aires
Hospital Materno Infantil Ramón Sardá Buenos Aires
Hospital Interzonal Alberto Antranik Eurnekian, provincia Buenos Aires
Hospital Municipal Materno Infantil Comodoro Hugo Cesar Meisner, provincia Buenos Aires
Hospital Comunal de Tigre, provincia Buenos Aires
Hospital Dr. Arturo Oñativia, provincia Buenos Aires
Hospital Dr. Carlos Bocalandro, provincia Buenos Aires
Hospital Héroes de Malvinas, provincia Buenos Aires
Hospital Magdalena V. de Martínez, provincia Buenos Aires
Hospital Mariano y Luciano de la Vega, provincia Buenos Aires
Hospital Municipal Ostaciana B. de Lavignolle, provincia Buenos Aires
Hospital Materno Infantil de San Isidro, provincia Buenos Aires
Hospital Virgen del Carmen, provincia Buenos Aires
Hospital J. B. Iturraspe, Santa Fe
Hospital Maternidad Nuestra Señora De Las Mercedes, Tucumán
Hospital Materno Infantil San Roque, Entre Ríos
Hospital Villa Dolores, Córdoba
Information provided by (Responsible Party):
begoña Martinez de Tejada, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00536003
First received: September 24, 2007
Last updated: June 5, 2012
Last verified: June 2012

September 24, 2007
June 5, 2012
July 2006
December 2012   (final data collection date for primary outcome measure)
The principal aim is to demonstrate that progesterone reduces preterm birth before 37 weeks of gestation [ Time Frame: end of pregnancy ] [ Designated as safety issue: No ]
The principal aim is to demonstrate that progesterone reduces preterm birth before 37 weeks of gestation [ Time Frame: end of pregnancy ]
Complete list of historical versions of study NCT00536003 on ClinicalTrials.gov Archive Site
Secondary aims are to show that progesterone 1) reduces preterm birth before 32 and before 34 weeks of gestation 2) reduces the number and duration of recurring episodes of preterm labor and 3) reduces perinatal mortality and morbidity, 4)Side effects [ Time Frame: end of pregnancy and 28 days after delivery ] [ Designated as safety issue: Yes ]
Secondary aims are to show that progesterone 1) reduces preterm birth before 32 and before 34 weeks of gestation 2) reduces the number and duration of recurring episodes of preterm labor and 3) reduces perinatal mortality and morbidity. [ Time Frame: end of pregnancy and 28 days after delivery ]
Not Provided
Not Provided
 
Vaginal Progesterone to Prevent Preterm Delivery in Women With Preterm Labor
Prevention of Preterm Delivery With Vaginal Progesterone in Women With Preterm Labor

The administration of vaginal progesterone, in addition to standard tocolysis, will decrease the risk of delivering prematurely and of recurrent preterm labor. We also hypothesize that the reduction in preterm delivery will be associated with a decrease in infant mortality and morbidity.

The principal aim is to demonstrate that progesterone reduces preterm birth before 37 weeks of gestation. Secondary aims are to show that progesterone 1) reduces preterm birth before 32 and before 34 weeks of gestation 2) reduces the number and duration of recurring episodes of preterm labor and 3) reduces infant mortality and morbidity.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Preterm Delivery
  • Morbidity
  • Perinatal Mortality
  • Drug: progesterone
    vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
    Other Name: Utrogestan
  • Drug: placebo
    vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
  • Experimental: 1
    Intervention: Drug: progesterone
  • Placebo Comparator: 2
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
384
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Gestational age between 240/7 et 336/7 weeks of gestation (based on a reliable estimate by ultrasound performed before 22 weeks)
  • Singleton pregnancy
  • Intact membranes
  • Preterm labor defined as:

    • 2 or more regular and painful uterine contractions in 10 minutes plus one or plus of the following criteria:
    • short cervix detected by vaginal ultrasound scanning (cervical length less than 30 mm until 31 weeks and less than 25 mm from 32 weeks)
    • cervical changes detected clinically (cervical length less or equal 10 mm or Bishop score less than 6
    • cervical changes during hospitalization (more or equal 5 mm between two clinical or US exams)
    • positive fetal fibronectin
  • Age ≥ 18 years old
  • Signed informed consent
  • Possible and accepted follow-up

Exclusion Criteria:

  • Multiple gestation
  • Cervical cerclage
  • Hydramnios (AFI >95th percentile for gestational age or greatest pocket >8 cm)
  • Premature rupture of membranes
  • Chorioamnionitis (criteria for clinical diagnosis are: elevated WBC, elevated CRP, maternal tachycardia, fetal tachycardia, uterine tenderness and/or amniotic fluid foul odor)
  • Cervical dilatation > 3 cm
  • Placenta praevia or abruptio placentae
  • Intra-uterine growth restriction or non-reassuring fetal status
  • Pre-eclampsia or severe hypertension
  • Any other maternal or fetal pathology which should indicate medically preterm delivery
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Switzerland
 
NCT00536003
CER: 04-196, matped 04-001
No
begoña Martinez de Tejada, University Hospital, Geneva
begoña Martinez de Tejada
  • Centre Hospitalier Universitaire Vaudois
  • University Hospital Inselspital, Berne
  • Basel Women’s University Hospital
  • University of Zurich
  • Kantonsspital Chur
  • Cantonal Hospital of St. Gallen
  • Luzerner Kantonsspital
  • Kantonsspital Winterthur KSW
  • Besins Laboratory, Belgium
  • Hospital Bernardino Rivadavia Buenos Aires
  • Hospital Carlos G. Durand Buenos Aires
  • CEMIC Buenos Aires
  • Hospital Donación Francisco Santojanni Buenos Aires
  • Hospital Dr. Cosme Argerich Buenos Aires
  • Hospital Dr. T. Alvarez Buenos Aires
  • Hospital Italiano de Buenos Aires
  • Hospital J. M. Penna Buenos Aires
  • Hospital Materno Infantil Ramón Sardá Buenos Aires
  • Hospital Interzonal Alberto Antranik Eurnekian, provincia Buenos Aires
  • Hospital Municipal Materno Infantil Comodoro Hugo Cesar Meisner, provincia Buenos Aires
  • Hospital Comunal de Tigre, provincia Buenos Aires
  • Hospital Dr. Arturo Oñativia, provincia Buenos Aires
  • Hospital Dr. Carlos Bocalandro, provincia Buenos Aires
  • Hospital Héroes de Malvinas, provincia Buenos Aires
  • Hospital Magdalena V. de Martínez, provincia Buenos Aires
  • Hospital Mariano y Luciano de la Vega, provincia Buenos Aires
  • Hospital Municipal Ostaciana B. de Lavignolle, provincia Buenos Aires
  • Hospital Materno Infantil de San Isidro, provincia Buenos Aires
  • Hospital Virgen del Carmen, provincia Buenos Aires
  • Hospital J. B. Iturraspe, Santa Fe
  • Hospital Maternidad Nuestra Señora De Las Mercedes, Tucumán
  • Hospital Materno Infantil San Roque, Entre Ríos
  • Hospital Villa Dolores, Córdoba
Principal Investigator: Begona Martinez de Tejada, MD, PhD University Hospital, Geneva
University Hospital, Geneva
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP